Eight patients with infectious mononucleosis, aged between 8 and 24, were studied for cell-mediated immunity by the in vitro leukocyte migration inhibition test at acute and convalescent stages. Follow-up studies were also carried out at up to 4 months after clinical illness. Cell-mediated immunity to EpsteinBarr virus (EBV) in the peripheral leukocytes from these patients was absent or incipient in all cases during the acute phase, although it was present in lymphocytes from a biopsied lymph node obtained from one of the patients. In contrast, cell-mediated immunity to EBV was detected readily in peripheral leukocytes obtained during convalescence and in the follow-up studies. A blocking factor that abrogated leukocyte migration inhibition induced by EBV antigen was detected in acute and convalescent sera obtained from six of eight patients, whereas serum antinuclear autoantibodies were detected in the two patients whose sera failed to block leukocyte migration inhibition. When sera were fractionated, this blocking effect was observed only in the serum immunoglobulin G fractions. In follow-up studies, neither the blocking factor nor the antinuclear autoantibodies were found in the sera collected.
It has been established that the Epstein-Barr herpesvirus (EBV) causes infectious mononucleosis, a benign lymphoproliferative illness (13) . Epidemiological evidence suggests that the occurrence of clinical infectious mononucleosis at the individual level and its prevalence at the population level are related inversely to the age of EBV infection (6, 7, 14, 18) and that serological status is an index of protection (6, 27) , since the disease arises only in individuals who have no serological evidence of previous exposure to the virus.
Cell-mediated immunity (CMI) is considered a primary factor in defense against infection with most viruses (1, 23) . However,-transient anergy as a manifestation of generalized depression of CMI associated with a variety of viral diseases and administration of viral vaccines has been reported (3, 25, 26, 28) . In an earlier study (19) we were able to demonstrate the presence of CMI to EBV in nornal subjects who had serum antibody to EBV and showed that CMI to EBV in five patients with acute infectious mononucleosis was not detected, despite the presence of antibody to EBV capsid ' Present address: National Cancer Institute, Bethesda, MD 20014 . 2 Present address: Papua New Guinea Institute of Medical Research, P.O. Box 60, Goroka, Papua, New Guinea.
antigen, but appeared in the convalescent phase of the illness. A blocking factor to EBV was also found in the acute and convalescent sera from these patients but not in normal subjects with serum EBV antibody (19) . The presence ofa blocking factor and the absence of CMI specific to EBV in acute infectious mononucleosis are of special interest, because the virus has also been incriminated in the pathogenesis of Burkitt's lymphoma and nasopharyngeal carcinoma (12, 15, 30) .
In this communication, we report on results obtained from studies carried out on another series ofeight patients and confirm our findings reported earlier on CMI to EBV in patients with infectious mononucleosis (19 (11, 18) , using SH-RP cells (20) previously ultraviolet irradiated for the enhancement of virus capsid antigen (17) .
Immunoelectroosmophoresis. Immunoelectroosmophoresis of serum IgG fractions was carried out according to Ouchterlony (24) (11, 18) , using SH-RP cells (17, 20) .
b Freshly collected leukocytes were used in the leukocyte migration inhibition test. Mean percent inhibition ± standard error (SE) was determined from a minimum of four replicate cultures. Twenty percent was considered positive, and <15% was considered negative. Peripheral leukocytes from all subjects failed to respond (<15%) to control antigen from Raji cells.
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b Freshly collected leukocytes and EBV antigen were used in the leukocyte migration inhibition test. Mean percent inhibition ± SE was determined from a minimum offour replicate cultures. Twenty percent or more was considered positive, and less than 15% was considered negative. Peripheral leukocytes from all subjects failed to respond to control antigen from Raji cells. and IgM antibodies to EBV were present, results obtained from the first blood samples collected at initial consultations are representative; these results are given in Table 3 . However, despite the fact that peripheral leukocytes from patient no. 4 in the acute stage of disease repeatedly gave insignificant migration-inhibitory response to EBV antigen, lymphoid cells from a biopsied lymph node taken at this phase gave a marked migrationinhibitory response (Table 3) .
At convalescence, when all clinical symptoms and hematological abnormalities had abated and when heterophile antibodies as well as IgM antibody to EBV had fallen to undetectable levels, significant inhibition (.20%) of migration could be detected when peripheral leukocytes from these patients were challenged by EBV antigen (Tables 2 and 3 ). This reactivity did not appear to wane and could be detected in peripheral leukocytes of these patients repeatedly, up to 4 months after the illness. Detailed results of two cases are given in Table 2 , whereas representative results for all cases, obtained from testing the first blood samples collected at convalescence and the last samples collected in follow-up, are given in Table 3 .
When challenged by control antigen prepared from Raji cells, peripheral leukocytes from normal adults and from patients at different stages of infectious mononucleosis did not respond.
Serum antibodies to EBV. All sera collected at the acute and convalescent phases of infectious mononucleosis as well as in follow-up studies had serum IgG antibody to capsid anti- (17, 21) . b Freshly collected leukocytes and EBV antigen were used in the leukocyte migration inhibition test. Mean percent inhibition ± SE was determined from a minimum of four replicate cultures. Twenty percent was considered positive, 15% was considered negative, and in-between was considered equivocal. Peripheral leukocytes from all subject failed to respond to control antigen from Raji cells.
c Acute infectious mononucleosis is defined clinically and hematologically in the presence of specific IgM to EBV and/or Paul-Bunnell heterophile antibodies. Results are those obtained from the first blood samples collected at initial consultations. d Convalescence is defined by the absence ofclinical, hematological, and serological evidence of infectious mononucleosis.
e Follow-up studies were carried out up to 4 months after clinical illness. Results are those obtained from the last blood samples.
f Leukocytes from a lymph node biopsy of this patient at the acute phase of infectious mononucleosis tested against EBV antigen and control antigen gave mean percentages of inhibition of 24.3 ± 1.8 and 7.2 ± 1.3, respectively. gen of EBV. In two of the patients, a significant rise in IgG titers could also be detected. Serum IgM antibody to EBV was detected in all acute sera; this varied in individuals and ranged from 1:16 to 1:128 (Table 3) . However, there is no correlation between the levels of specific antibodies (IgG and IgM) to EBV and the level of leukocyte migration-inhibitory response (Tables 2 and 3). ANF. ANF was detected in two of the eight patients with acute infectious mononucleosis (cases 4 and 5, a IM, Infectious mononucleosis patient; NA, normal adult. b Titers measured as the reciprocal of the greatest serum dilution at which the blocking effect on EBVinduced migration inhibition of autologous leukocytes is still detectable.
" Freshly collected autologous leukocytes or heterologous leukocytes whose migration was known to be inhibited by EBV were challenged by a mixture of EBV antigen and test serum in the leukocyte migration inhibition test. Percent inhibition is expressed as mean ± SE, derived from a minimum of four replicate cultures; 20% or greater is positive, less than 15% is negative, and in-between is equivocal. In all cases insignificant migration inhibition responses were obtained when autologous or heterologous leukocytes were challenged by serum alone, in the absence of EBV antigen. * Indicates abrogation of expected leukocyte migration inhibition.
d In IM patients, migration inhibition was determined by using autologous leukocytes collected at follow-up studies. Migration inhibition values of these leukocytes to EBV in the presence of heat-inactivated fetal bovine serum are given in Table 3 .
e Migration inhibition was determined by using leukocytes from a normal subject whose migration was known to be inhibited by the EBV antigen preparation in the presence of heat-inactivated fetal bovine serum; percent inhibition was 23. Serum blocking factor. Ofthe eight patients tested, a blocking effect on EBV-induced migration inhibition of autologous and heterologous leukocytes was found in six sera collected at the acute phase, in seven collected at convalescence, and in none of the sera collected in the follow-up studies. Detailed results are given in Table 4 . The titer of blocking factor in each serum collected from the eight patients with infectious mononucleosis is given in Table 4 . The titers of blocking factor do not correlate with serum antibody titers to EBV (Tables 3  and 4 ). Sera from normal adults did not show any blocking effect on migration inhibition of leukocytes whose migration was known to be inhibited by EBV antigen in the presence of fetal bovine serum (Table 4) .
When IgG and IgM fractions of acute sera collected from three of the eight patients were tested, a blocking effect on autologous leukocyte migration inhibition induced by the EBV antigen was observed in the IgG fractions, but not in the IgM fractions.
Immunodiffusion (4) , in which the paracortex, a thymusdependent zone not primarily involved in antibody formation, is found to be hyperactive.
Although the migration inhibition test has been reported to correlate well with delayedtype hypersensitivity (9) and involves the production of a migration inhibition factor (16, 29) , it is still an open question whether cellular immune reaction detected by this assay is exclusively a T cell fumction. We are aware of the shortcomings in using a single in vitro correlate to detect CMI and are, therefore, developing an antigen-stimulated blastogenic test as well as an interferon release assay to complement our study on cellular immunity to EBV in patients with infectious mononucleosis.
Intense antibody fornation in infectious mononucleosis has long been recognized. Humoral antibodies include heterophile antibodies, EBV antibodies, and a battery of hetero-, iso-, and autoantibodies. This intense antibody response is unique among infectious diseases and is equalled only occasionally in Sjogren's disease and systemic lupus erythematosus (5) . However, the role of these antibodies, especially EBV-associated antibodies, in the control of infectious mononucleosis is obscure.
Recently, a blocking factor that abrogates CMI to EBV detected by the leukocyte migration inhibition test has been described in sera collected from patients with infectious mononucleosis (19) . This serum blocking effect is probably specific to EBV, since it fails to negate CMI response to an unrelated antigen such as one prepared from Escherichia coli (19) . In the present study, we have demonstrated that acute and convalescent sera collected from patients with infectious mononucleosis were able to abrogate in vitro leukocyte migration-inhibitory response to EBV, whereas sera collected from the same patients in follow-up studies up to 4 months after the illness failed to block EBV-induced leukocyte migration inhibition. It is impossible to say whether this blocking factor is simply an IgG antibody or, more generally, whether it is a product of infected or normal B cells, since although it is found in the IgG fraction, immunoelectroosmophoretic study of the fraction gave multiple precipitation lines.
The precise function ofthis blocking factor in vivo is unknown, although it interferes with leukocyte migration inhibition in vitro, as shown in the present study. It is thus not clear whether this blocking action demonstrated in vitro contributes to the intensive but self-limiting lymphoproliferation seen in infectious mononucleosis in vivo.
In acute viral hepatitis, it has been postulated that a hyperactive T cell response is responsible for the development offulminant hepatitis in 1% of patients and results in severe liver cell necrosis, whereas impaired T cell function is responsible for the development of a hepatitis B antigen carrier state in 10% of patients and gives rise to slow, progressive, chronic liver disease (22) . It is possible that the blocking factor detected in this study is part of the normal negative feedback mechanism involved in immunity to virus infection. Destruction of EBV-carrying cells in vivo may result in the release of autoantigen, and this process may have been enhanced by the absence of blocking-factor production as well as by a reduced efficiency of normal control mechanism against autoantibody formation (cases 4 and 5, Table 4 ).
The interrelationship between the humoral and cell-mediated components of immunity is obviously complex, and further information on this delicate immunological balance in EBV infection may help elucidate the pathogenesis of EBV-related diseases and other persistent viral infections. 
